High-dose therapy with stem cell rescue

John W. Sweetenham

doi:10.1201/b13424

High-dose therapy with stem cell rescue

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

High-dose therapy (HDT) and stem cell transplantation (SCT) has been in widespread use in the treatment of Hodgkin (HL) and non-Hodgkin lymphomas (NHLs) for more than 20 years. Despite this, the impact of this treatment on remission duration and overall survival for patients with these diseases remains poorly defined. High-dose therapy with autologous stem cell transplantation (ASCT) is now regarded as the standard of care for certain patients with relapsed and refractory HL or relapsed aggressive B cell NHL. This is supported by results from prospective, randomized clinical trials. The role of HDT and ASCT as a component of first-line therapy for certain ‘high risk’ patients with HL and NHL is also being better defined as results emerge from recently completed randomized studies.

Original language	English (US)
Title of host publication	The Lymphoid Neoplasms 3ed
Publisher	CRC Press
Pages	954-969
Number of pages	16
ISBN (Electronic)	9781444113228
ISBN (Print)	9780340809471
DOIs	https://doi.org/10.1201/b13424
State	Published - Jan 1 2010
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1201/b13424

Cite this

@inbook{ba1b2bae71fc4a50b4aa11c3d7df40dd,

title = "High-dose therapy with stem cell rescue",

abstract = "High-dose therapy (HDT) and stem cell transplantation (SCT) has been in widespread use in the treatment of Hodgkin (HL) and non-Hodgkin lymphomas (NHLs) for more than 20 years. Despite this, the impact of this treatment on remission duration and overall survival for patients with these diseases remains poorly defined. High-dose therapy with autologous stem cell transplantation (ASCT) is now regarded as the standard of care for certain patients with relapsed and refractory HL or relapsed aggressive B cell NHL. This is supported by results from prospective, randomized clinical trials. The role of HDT and ASCT as a component of first-line therapy for certain {\textquoteleft}high risk{\textquoteright} patients with HL and NHL is also being better defined as results emerge from recently completed randomized studies.",

author = "Sweetenham, {John W.}",

year = "2010",

month = jan,

day = "1",

doi = "10.1201/b13424",

language = "English (US)",

isbn = "9780340809471",

pages = "954--969",

booktitle = "The Lymphoid Neoplasms 3ed",

publisher = "CRC Press",

}

TY - CHAP

T1 - High-dose therapy with stem cell rescue

AU - Sweetenham, John W.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - High-dose therapy (HDT) and stem cell transplantation (SCT) has been in widespread use in the treatment of Hodgkin (HL) and non-Hodgkin lymphomas (NHLs) for more than 20 years. Despite this, the impact of this treatment on remission duration and overall survival for patients with these diseases remains poorly defined. High-dose therapy with autologous stem cell transplantation (ASCT) is now regarded as the standard of care for certain patients with relapsed and refractory HL or relapsed aggressive B cell NHL. This is supported by results from prospective, randomized clinical trials. The role of HDT and ASCT as a component of first-line therapy for certain ‘high risk’ patients with HL and NHL is also being better defined as results emerge from recently completed randomized studies.

AB - High-dose therapy (HDT) and stem cell transplantation (SCT) has been in widespread use in the treatment of Hodgkin (HL) and non-Hodgkin lymphomas (NHLs) for more than 20 years. Despite this, the impact of this treatment on remission duration and overall survival for patients with these diseases remains poorly defined. High-dose therapy with autologous stem cell transplantation (ASCT) is now regarded as the standard of care for certain patients with relapsed and refractory HL or relapsed aggressive B cell NHL. This is supported by results from prospective, randomized clinical trials. The role of HDT and ASCT as a component of first-line therapy for certain ‘high risk’ patients with HL and NHL is also being better defined as results emerge from recently completed randomized studies.

UR - http://www.scopus.com/inward/record.url?scp=85056037488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056037488&partnerID=8YFLogxK

U2 - 10.1201/b13424

DO - 10.1201/b13424

M3 - Chapter

AN - SCOPUS:85056037488

SN - 9780340809471

SP - 954

EP - 969

BT - The Lymphoid Neoplasms 3ed

PB - CRC Press

ER -

High-dose therapy with stem cell rescue

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this